Drug – bio-affecting and body treating compositions – Nonspecific immunoeffector – per se ; or nonspecific...
Reexamination Certificate
2006-05-09
2006-05-09
Huff, Sheela J. (Department: 1643)
Drug, bio-affecting and body treating compositions
Nonspecific immunoeffector, per se ; or nonspecific...
C424S085400, C424S085100, C424S085200, C424S085700, C530S351000, C514S002600
Reexamination Certificate
active
07041301
ABSTRACT:
A method for reducing the recurrence of a resectable malignant tumor includes administering an immunostimulatory dosage of an α-interferon composition, then surgically resecting the malignant tumor. A method for treating a human patient having a non-resectable malignant tumor includes administering an immunostimulatory dosage of an α-interferon composition to the patient and treating the patient with effective non-surgical medical methodologies to diminish the tumor. An article of manufacture combines an α-interferon composition within a packaging material and a package label or insert indicating that administration of an immunostimulatory dosage of an α-interferon composition followed by surgical resection of a malignant tumor can be effective for treating a human patient having the malignant tumor.
REFERENCES:
patent: 4846782 (1989-07-01), Bonnem
patent: 5997858 (1999-12-01), Tovey et al.
patent: 6063373 (2000-05-01), Hellstrand et al.
Kokoschka, E.-M. et al., J. Invest. Dermatol. 95: 193S-197S, 1990.
Nichols, P.H. et al. Clin. Exp. Immunol. 94: 4-10, 1993.
Brittenden, J. et al. Natural Killer Cells and Cancer. Cancer, 77(7): 1226-1243, Apr., 1996.
Lennard, T.W.J. et al. the influence of surgical operations on components of the human immune system. Br. J. Surg., 72: 771-776, 1985.
Roitt, I.M. et al. Immunology. 3rd Edition, Mosby, St. Louis, pp. 2.5-2.7, 1993.
Illustrated Stedman's Medical Dictionary, 24th Edition, Williams & Wilkins, Baltimore, p. 707, 1982.
Ibayashi et al., “Regression of Pulmonary and Multiple Skeletal Metastases from Renal Cell Carcinoma by Nephrectomy and Alpha-interferon Therapy: A Case Report,”Jpn. J. Clin. Oncol.,1993, 23(6):378-383.
Mahvi et al., “Interferon α enhances expression of TAG-72 and carcinoembryonic antigen in patients with primary colorectal cancer,”Cancer Immunol. Immunother.,1995, 40:311-314.
Monkarsh et al., “Positional Isomers of Monopegylated Interferon α-2a: Isolation, Characterization, and Biological Activity,”Analytical Biochemistry, 1997, 247:434-440.
Agarwala, S. et al., “Interferons in the Therapy of Solid Tumors,” Oncology, 51:129-136 (1994).
Borden, E., “Interferons: Rationale for Clinical Trials in Neoplastic Disease,” Annals of Internal Medicine, 91:472-479 (1979).
Brenner, B. et al., “Natural Killer Cell Function in Patients With Acquired Immunodeficiency Syndrome and Related Diseases,” Journal of Leukocyte Biology, 46:75-83 (1989).
Burchell, J. et al., “Complexity of Expression of Antigenic Determinants, Recognized by Monoclonal Antibodies HMFG-1 and HFMG-2, In Normal and Malignant Human Mammary Epithelial Calls,” The Journal of Immunology, 131(1):508-513 (1983).
Edwards, B. et al., “Comparative in Vivo and in Vitro Activation of Human Natural Killer Cells by Two Recombinant α-Interferons Differing in Antiviral Activity,” Cancer Research, 44:3135-3139 (1984).
Edwards, B. et al., “Low Doses of Interferon Alpha Result in More Effective Clinical Natural Killer Cell Activation,” J. Clin. Invest., 75:1908-1913 (1985).
Einhorn, S. et al., “Interferon and Natural Killer Activity in Multiple Myeloma . . . ,” Int. J. Cancer, 30:167-172 (1982).
Einhorn, S. et al., “Interferon and Spontaneous Cytotoxicity in Man,” Acta. Med. Scand., 204:477-483 (1978).
Golub, S. et al., “Systemic Administration of Human Leukocyte Interferon to Melanoma Patients . . . ,” JNCI, 68(5):703-710 (1982).
Gresser, I. et al., “Mechanism of the Antitumour Effect of Interferon in Mice,” Nature, 239:167-168 (1972).
Kalvakolanu, D. et al., “An Overview of the Interferon System: Signal Transduction and Mechanisms of Action,” Cancer Investigation, 14(1):25-53 (1996).
Kopp, W. et al., “Immunological Monitoring and Clinical Trials of Biological Response Modifiers,” Cancer Chemotherapy and Biological Response Modifiers, 15:226-286 (1994).
Krown, S. et al., “High-Dose Human Lymphoblastoid Interferon in Metastatic Colorectal Cancer: Clinical Results and Modification of Biological Responses,” Cancer Treatment Reports, 71(1):39-45 (1987).
Kutza, J. et al., “The Effects of General Anesthesia and Surgery on Basal and Interferon Stimulated Natural Killer Cell Activity of Humans,” Anesth. Analg., 85:918-923 (1997).
Laszlo, J. et al., “Phase I Study of Pharmacological and Immunological Effects of Human Lymphoblastoid Interferon Given to Patients with Cancer,” Cancer Res., 43:4458-4466 (1983).
Lucero, M. et al., “Comparison of Effects of Leukocyte and Fibroblast Interferon on Immunological Parameters in Cancer Patients,” Eur. J. Cancer Clin. Oncol., 18(3):243-251 (1982).
Maluish, A. et al., “Depression of Natural Killer Cytotoxicity After In Vivo Administration of Recombinant Leukocyte Interferon,” The Journal of Immunology, 131(1):503-507 (1983).
Maffezzini, M., “Treatment of Advanced Metastatic Renal Cell Carcinoma With Recombinant Interleukin-2-Based Immunotherapy Regimens: The Restrictedness of the Results Should not Generate Disbelief,” The Cancer Journal, 10(3):140-142 (1997).
Markovic, S. et al., “Anesthesia Inhibits Interferon-Induced Natural Killer Cell Cytotoxicity via Induction of CD8+Suppressor Cells,” Cellular Immunology, 151:474-480 (1993).
Markovic, S. et al., “Anesthesia Inhibits Poly I:C Induced Stimulation of Natural Killer Cell Cytotoxicity in Mice,” Clinical Immunology and Immunopathology, 56:202-209 (1990).
Markovic, S. et al., “Inhibition of Induction of Natural Killer Activity in Mice by General Anesthesia (Avertin): Role of Interferon,” Clinical Immunology and Immunopathology, 60:181-189 (1991).
Markovic, S. et al., “Inhibition of Interferon Stimulation of Natural Killer Cell Activity in Mice Anesthetized with Halothane or Isoflurane,” Anesthesiology, 78(4):700-706 (1993).
Markovic, S. et al., “Neoadjuvant Immunotherapy With Interferon of the Spontaneously Metastasizing Murine B16F10L Melanoma,” Int. J. Cancer, 45:788-794 (1990).
Markovic, S. et al., “Role of Natural Killer and T-Cells in Interferon Induced Inhibition of Spontaneous Metastases of the B16F10L Murine Melanoma,” Cancer Research, 51:1124-1128 (1991).
Neefe, J. et al., “Augmented Immunity in Cancer Patients Treated with α-Interferon,” Cancer Research, 45:874-878 (1985).
Nichols, P. et al., “Peri-operative Modulation of Cellular Immunity in Patients with Colorectal Cancer,” Clin. Exp. Immunol., 94:4-10 (1993).
Pape, G. et al., “Kinetics of Natural Cytotoxicity in Patients Treated with Human Fibroblast Interferon,” Cancer Immunology and Immunotherapy, 11:1-6 (1981).
Rohatiner, A. et al., “Management of Follicular Lymphoma,” Oncology, 6:473-479 (1994).
Sedman, P. et al., “Effects of Low Dose Perioperative Interferon on the Surgically Induced Suppression of Antitumour Immune Responses,” Br. J. Surg., 75:976-981 (1988).
Seiden, M. et al., “Multiple Myeloma,” Current Opinion in Oncology, 6:41-49 (1994).
Shapiro, R. et al., “Remission of Nephrotic Syndrome of HBV-Associated Membranous Glomerulopathy following Treatment with Interferon,” Am. J. Nephrology, 15:343-347 (1995).
Toliou, Th. et al., “Natural Killer Cell Activation After Interferon Administration in Patients with Metastatic Renal Cell Carcinoma: An Ultrastructural and Immunohistochemical Study,” Eur. Urol., 29:252-256 (1996).
Ucar R., et al., “Interferons: Their Role in Clinical Practice,” Annals of Allergy Asthma & Immunology, 75:377-386 (1995).
Urabe, A., “Interferons for the Treatment of Hematological Malignancies.” Oncology, 51:137-141 (1994).
Fish & Richardson P.C. P.A.
Huff Sheela J.
Mayo Foundation for Medical Education and Research
LandOfFree
Interferon immunotherapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Interferon immunotherapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interferon immunotherapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3596823